For healthcare professionals

LibiTight Femme Gel — clinical resource

A reference page for gynecologists, pharmacists, and other clinicians evaluating LibiTight as a non-hormonal option for vaginal-health indications. Sections below cover mechanism, evidence, dosing per indication, safety profile, and counseling points. Composition percentages remain on the technical file (available on request).

At a glance

Clinical summary

Product class
Topical non-hormonal vaginal gel
Indications
Vaginal dryness, dyspareunia, vulvovaginal atrophy, vaginal symptoms of menopause, postpartum dryness.
Active ingredients
Hyaluronic acid, chamomile extract (Matricaria recutita), allantoin, L-arginine, potassium alum.
Mechanism summary
Combined action of hydration (HA), anti-inflammatory soothing (chamomile), barrier protection (allantoin), and tissue support (L-arginine, potassium alum) via topical application.
Hormonal status
Non-hormonal. No systemic estrogen exposure.
Positioning
Suitable when HRT is contraindicated, not tolerated, or not preferred. Also for short-term symptom relief alongside HRT or other therapies.
Standard dosing
2 ml once or twice daily depending on indication; typical 10-day course. See Dosing section for indication-specific guidance.
Manufacturing
Made by Goodness Care, Amman, Jordan. ISO- and GMP-compliant facility.

Mechanisms of action

How the formula works

LibiTight's five-active formula combines complementary mechanisms — hydration, anti-inflammatory soothing, barrier protection, and tissue support — delivered through topical application. Each active's role is described individually below; proportions remain on the technical file. Most mechanism data comes from preclinical and clinical work on the individual actives, not on the LibiTight formulation specifically.

Hyaluronic acid

Sodium Hyaluronate

Hyaluronic acid is a glycosaminoglycan that binds water at up to 1,000 times its molecular weight. Topically applied, it forms a hydrating film on mucosal surfaces and penetrates the upper stromal layer where it integrates with the tissue's native HA matrix. The result is sustained moisture retention, improved tissue compliance, and reduced friction during physical contact. HA also supports keratinocyte and fibroblast activity in the epithelial layers.

Clinical relevance

Primary active for vaginal dryness, vulvovaginal atrophy, and dyspareunia of friction etiology. Mechanism well-supported by clinical evidence covering Studies 1 through 4 on the Clinical Evidence page, including head-to-head comparison with topical estrogen for VVA.

Chamomile extract

Matricaria Recutita Flower Extract

Chamomile (Matricaria recutita) extract contains apigenin, bisabolol, chamazulene, and matricin among its bioactive constituents. Apigenin has documented binding affinity for estrogen receptor β (ER-β) — a phytoestrogen-class action that may contribute to local tissue effects without systemic estrogenic activity. The extract's anti-inflammatory action operates through inhibition of NF-κB and COX-2 pathways; its antioxidant action quenches reactive oxygen species in irritated tissue.

Clinical relevance

Contributes to symptomatic relief in dyspareunia, vulvovaginal atrophy, and conditions where local inflammation underlies discomfort. The phytoestrogen-class receptor binding is mechanistic; therapeutic effect is symptom-focused, not hormone-replacement.

Phytoestrogen-class language here refers to ER-β binding affinity demonstrated in vitro and in receptor-binding assays. This does not equate to systemic estrogen replacement; topical application is the operative mode.

Allantoin

Allantoin

Allantoin (5-ureidohydantoin) acts as a keratolytic and cell-proliferation stimulant. It softens the keratinous layer of epithelial surfaces, supports keratinocyte migration during tissue turnover, and forms a protective film over abraded or irritated surfaces. Allantoin is non-irritating at concentrations used in topical formulations and has well-characterized safety in mucosal applications.

Clinical relevance

Supportive role across all indications, particularly relevant where tissue surfaces are friable, thinned, or healing (postpartum recovery, vulvovaginal atrophy). Complements HA's hydration effect by maintaining the surface barrier.

L-Arginine

Arginine

L-arginine is the endogenous substrate for nitric oxide synthase (NOS). Topically applied, the proposed mechanism is conversion to nitric oxide by tissue NOS enzymes, leading to local smooth muscle relaxation and increased microvascular blood flow. Effect is dose-dependent and contingent on local enzyme activity; the topical mode is mechanistically distinct from oral administration.

Clinical relevance

Supportive role in formulas targeting tissue blood flow as a contributor to comfort and mucosal health. Topical bioavailability and local tissue effects are mechanism-supported. Most published L-arginine trials for related endpoints use oral administration.

Topical and oral L-arginine pharmacokinetics differ substantially. Most published trials studying L-arginine for sexual or reproductive-health endpoints use oral administration; topical bioavailability and the consequent local tissue effects are less extensively documented in the formulation context. The single relevant study cited on the Clinical Evidence page (Study 6) uses topical administration.

Potassium alum

Potassium Alum

Potassium alum (KAl(SO₄)₂·12H₂O) is a coordination compound with astringent and antimicrobial properties. Topically applied, it causes protein coagulation at the surface, contracting tissue and reducing surface secretions. The astringent effect is local and reversible. Antimicrobial action operates through pH modification and disruption of bacterial membrane integrity.

Clinical relevance

Contributes to the formula's tissue-tone character and reduces microbial growth on vaginal surfaces. Supportive role in formulations aimed at restoring surface tone and reducing irritation. Long history of safe topical mucosal use at appropriate concentrations.

Clinical evidence summary

Published trials covering five clinical questions

Mechanism data on LibiTight's actives comes from peer-reviewed published trials. Each is summarized in detail on the Clinical Evidence page with full citations and PubMed/PMC identifiers. The studies are on the actives, not on the LibiTight formulation specifically — a discipline maintained throughout this resource.

  • Hyaluronic acid for vaginal dryness (1 trial)
  • Hyaluronic acid for vulvovaginal atrophy (2 trials)
  • Hyaluronic acid compared to topical estrogen (1 trial)
  • Chamomile for dyspareunia (1 trial)
  • L-arginine for topical tissue support (1 trial)
See full clinical evidence

Dosing & administration

Three core dosing regimens

LibiTight's dosing is organized around three regimens corresponding to clinical use cases: symptomatic relief, tissue support, and on-demand pre-intimacy. Each is described below, with the indications it addresses and clinical guidance for follow-up. The 2 ml dose and topical application are constant; what varies is frequency, course duration, and clinical context.

Symptomatic relief

Dose
2 ml
Frequency
Twice daily
Duration
10 days

Indications

Vaginal dryness, itching, burning sensations, mild dyspareunia of friction etiology.

Apply with the included applicator. Patient should remain supine for 5 minutes after application. Symptom improvement typically observed within 5–7 days.

If symptoms persist beyond the 10-day course, gynecological consultation recommended to rule out alternative etiology.

Tissue support

Dose
2 ml
Frequency
Twice daily
Duration
20 days

Indications

Vulvovaginal atrophy, postpartum dryness (after the 6-week postnatal check), perimenopausal and menopausal tissue support.

Same application technique as the symptomatic regimen. Designed for conditions involving tissue changes rather than acute symptoms.

May be followed by intermittent maintenance dosing (2 ml twice weekly) for chronic conditions. Long-term use should be discussed with the patient's gynecologist.

On-demand pre-intimacy

Dose
2 ml
Frequency
As needed
Duration
30 minutes before activity

Indications

For tissue tone and comfort prior to intimacy. Can be used alongside the symptomatic or tissue-support regimens.

Apply 30 minutes before activity. Combined astringent and lubricating effect; effect is local and temporary.

For patients combining indications (e.g., postmenopausal dryness with pre-intimacy concerns), the symptomatic or tissue-support regimen addresses the underlying dryness while this on-demand regimen addresses acute pre-activity needs.

Safety profile

Topical, non-hormonal — established safety in routine use

LibiTight's safety profile is anchored in the topical, non-hormonal nature of its formulation. Active ingredients have established safety records in mucosal applications, and the absence of systemic absorption limits the contexts in which contraindications or interactions matter. The blocks below cover what HCPs need to know in routine practice.

Contraindications

Known hypersensitivity to any ingredient. Active vaginal infections of bacterial, fungal, or viral origin — treat the underlying infection first; LibiTight may be used after resolution. Documented allergy to chamomile or the Asteraceae plant family. Not indicated for patients under 18 years of age.

Drug interactions

No clinically significant systemic interactions documented. The topical, non-hormonal application profile makes interactions with oral medications — including HRT, anticoagulants, antihypertensives, and hormonal contraceptives — unlikely. When combining with other intravaginal preparations, separate applications by at least 30 minutes to allow for proper absorption of each.

Pregnancy and breastfeeding

Not specifically contraindicated in pregnancy or breastfeeding. Use during pregnancy should be discussed with the obstetric provider, particularly in the first trimester. During breastfeeding, the topical, non-hormonal profile and absence of systemic absorption support use as needed; recommend discussion with the patient's healthcare provider, particularly during the first six weeks postpartum. The actives' breast-milk pharmacokinetic data are limited; the topical-only application mitigates exposure risk.

Adverse effects

Adverse effects are uncommon and typically mild. Reported events include local irritation or burning at the application site (usually self-limiting and resolving with continued use), transient stinging on initial application (resolves within 1–2 uses), and rare contact sensitivity reactions, particularly to chamomile in patients with Asteraceae sensitivity. No serious adverse events documented in routine use. Discontinue if symptoms worsen or hypersensitivity develops.

Special populations

Cancer history: appropriate for women with hormone-sensitive cancer history (e.g., breast cancer, endometrial cancer) where systemic estrogen is contraindicated — the non-hormonal profile is a primary clinical advantage in this population. Diabetes: no dosing adjustments required. Renal or hepatic impairment: no adjustments needed; topical application minimizes systemic considerations. Elderly patients (>65): appropriate at standard dosing — particular relevance for vulvovaginal atrophy. Pediatric use: not indicated in patients under 18 years.

Patient counseling

Ten points for discussing LibiTight with patients

Practical guidance for the conversations clinicians have with patients about LibiTight. These ten points cover positioning, expectation-setting, audience-specific framing, and follow-up — drawn from common clinical conversations and the editorial conventions of this resource. Each can be cited by number in clinical notes or shared with practice staff.

  1. Position LibiTight as non-hormonal and topical from the start. Many patients with hormone concerns — cancer history, cardiovascular conditions, personal preference — find this the deciding factor. The mechanism is local; there's no systemic estrogen exposure to discuss.

  2. Set realistic timing expectations. For the 10-day symptomatic regimen, improvement typically begins within 5–7 days. For the 20-day tissue support regimen, benefits build through the course. Acute relief on day 1 is not the expected pattern; sustained improvement over the course is.

  3. For patients on HRT, LibiTight is complementary, not competitive. It addresses local symptoms that systemic HRT may not fully resolve, particularly vaginal dryness and atrophy that persist despite oral or transdermal estrogen. Discuss as adjunct, not as replacement.

  4. Vaginal health is often a topic patients hesitate to raise. Initiate directly: "Have you noticed changes in vaginal comfort, dryness, or intimate sensation?" Normalizing the question encourages disclosure and saves consultation time on indirect routes.

  5. For patients with hormone-sensitive cancer history (breast, endometrial), lead with the non-hormonal profile. Many in this population are uncertain whether topical interventions are safe; the topical, non-systemic mode of action provides the reassurance their oncologist's caution about HRT may have left ambiguous.

  6. For postpartum patients, frame dryness as a normal physiological consequence of breastfeeding-related low estrogen. LibiTight can provide comfort during that period; recommend discussion with their provider during the first six weeks postpartum, but use beyond that point is generally appropriate.

  7. If sexual function concerns are part of the conversation, address what LibiTight does (local tissue comfort, friction reduction) and refer to specialized care (sexual medicine, psychosexual counseling) for the dimensions it doesn't address. Setting this boundary protects both the patient and the product positioning.

  8. Clarify the dosing structure verbally. Twice daily is for the active course (10 or 20 days), not indefinite. Maintenance for chronic conditions is twice weekly. On-demand pre-intimacy is a separate, complementary use. Patients sometimes over-apply or under-apply without this framing.

  9. Confirm proper application technique: applicator use, supine position for 5 minutes after application. This matters particularly for elderly patients new to intravaginal medications and for patients with limited mobility. Demonstration with the included applicator improves first-time success rates.

  10. Set a follow-up timeline at the time of recommendation. Symptomatic regimen: review at 2–3 weeks. Tissue support regimen: review at 4–6 weeks. Document patient-reported outcomes — symptom severity, sexual comfort if relevant, tolerability — to inform next-step decisions.

Resources & contact

Practical pathways for healthcare professionals

Three direct paths for healthcare professionals working with LibiTight: sample requests for clinical evaluation, technical file access for in-depth composition and regulatory data, and direct medical affairs contact for clinical conversations. All channels are staffed by Goodness Care.

Request samples

For clinical evaluation in your practice or trial dispensing to selected patients. Sample requests are coordinated through Goodness Care's medical affairs.

Message on WhatsApp

Technical file

Composition details, manufacturing data, regulatory documentation, and stability information. Available to verified healthcare professionals on request.

Request by email

Talk to medical affairs

For clinical questions, study collaboration inquiries, adverse event reports, or any topic where direct contact with our medical team is the right path.

Message on WhatsApp

One more thing

Have a clinical question?

Our medical affairs team is available for any question about LibiTight — mechanism, dosing, safety in specific populations, study collaboration, adverse event reporting, or topics this resource didn't address.

Talk to medical affairs